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The obligate intracellular bacterial pathogen
Chlamydia trachomatis injects numerous effector
proteins into the epithelial cell cytoplasm to manipu-
late host functions important for bacterial survival. In
addition, the bacterium secretes a serine protease,
chlamydial protease-like activity factor (CPAF).
Although several CPAF targets are reported, the
significance of CPAF-mediated proteolysis is unclear
due to the lack of specific CPAF inhibitors and the
diversity of host targets. We report that CPAF also
targets chlamydial effectors secreted early during
the establishment of the pathogen-containing vac-
uole (‘‘inclusion’’). We designed a cell-permeable
CPAF-specific inhibitory peptide and used it to deter-
mine that CPAF prevents superinfection by degrad-
ing early Chlamydia effectors translocated during
entry into a preinfected cell. Prolonged CPAF inhibi-
tion leads to loss of inclusion integrity and caspase-
1-dependent death of infected epithelial cells. Thus,
CPAF functions in niche protection, inclusion integ-
rity and pathogen survival, making the development
of CPAF-specific protease inhibitors an attractive
antichlamydial therapeutic strategy.
INTRODUCTION
The obligate intracellular bacterial pathogen Chlamydia
trachomatis primarily infects epithelial cells of the urogenital
tract and the conjunctiva (Adderley-Kelly and Stephens, 2005)
that can lead to severe complications such as pelvic inflammatory
disease, ectopic pregnancy, and infertility. Similarly, ocular infec-
tions can lead to trachoma, the leading cause of infectious blind-
ness worldwide (Hu et al., 2010). Infection is initiated by attach-
ment and entry of elementary bodies (EBs), the infectious form
of Chlamydia, into epithelial cells. Upon entry, EBs transition into
replicative reticulatebodies (RBs) andestablishaparasitophorousCvacuole (‘‘inclusion’’) thatprevents fusionwith lysosomalcompart-
ments. At mid to late stages of infection, RBs revert back to EBs
and are released to infect neighboring cells (Belland et al., 2003).
C. trachomatis employs a type III secretion (T3S) system to
translocate virulence proteins directly into the cytoplasm of the
host cell. These effector proteins mediate cell invasion, rerouting
of membrane transport, and manipulation of signaling pathways
that are important in immunity (Valdivia, 2008). More than 5% of
Chlamydia’s genome is predicted to encode T3S effector
proteins (Arnold et al., 2009), including a family of inclusion
membrane proteins (Incs) that reside at the interface of the
host cytoplasm and inclusion membrane (Scidmore-Carlson
et al., 1999). These proteins are implicated in the modulation of
various host cellular functions, including membrane transport,
apoptosis, and microtubule dynamics (Betts et al., 2009). Unfor-
tunately, because of Chlamydia’s obligate intracellular lifestyle
and lack of tools for genetic manipulation, most putative chla-
mydial effectors remain poorly characterized.
In addition to T3S effectors, proteins that use the general
secretion pathway can access the host cell cytoplasm to manip-
ulate host cellular processes (Chen et al., 2010). A prominent
example is the chlamydial protease-like activity factor (CPAF),
a serine protease that is first secreted into the inclusion lumen
and eventually crosses the inclusion membrane (Zhong et al.,
2001). CPAF cleaves transcription factors (RFX5 and USF1)
required for the expression of antigen presentation molecules
(MHC) (Zhong et al., 2001), the proapoptotic factors Bim and
Puma (Pirbhai et al., 2006; Zhong et al., 2001), and p65/RelA,
a transcription factor required for NF-kB signaling (Christian
et al., 2010). Recently, there has been an expanding list of identi-
fied CPAF targets, underscoring the multiple roles played by this
protease in thebiologyofChlamydia infections.CPAFcleaves the
adherence junction protein nectin1 (Sun et al., 2008), the MHC-
like protein CD1d (Kawana et al., 2007), the proinflammatory
protein HMGB1 (Yu et al., 2010), the mitotic cell cycle regulator
Cyclin B, and PARP—a mediator of DNA damage during
apoptosis (Paschen et al., 2008). CPAF also remodels interme-
diate filaments (Dong et al., 2004; Kumar and Valdivia, 2008)
that circumscribe the inclusion to maintain its integrity and limit
the exposure of inclusion contents to cytoplasmic microbial
pattern recognition receptors (Kumar and Valdivia, 2008).ell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc. 21
Figure 1. CPAF Cleaves a Subset of Early Chla-
mydial Effectors
(A) RecombinantChlamydiaORFs (n = 309) were tested for
sensitivity to host- and bacterial-derived proteases.
(B) Recombinant CPAF cleaved chlamydial substrates in
a cell-free proteolysis assay. Approximately 40 ng purified
his-tagged CPAF was incubated with 48 mg GST-tagged
Chlamydia proteins at 37C for 20 min with increasing
concentrations of lactacystin. Cleavage products were run
on an SDS-PAGE gel and visualized with Coomassie blue.
(C)Schematic summaryof bacterial targets ofCPAF.CPAF
specifically cleaves chlamydial effectors translocated
during EB entry and early inclusion biogenesis, with the
exception of Ct813, which is transcribed starting at 8 hpi.
(D) The steady-state levels of the Inc CPAF substrates
decrease at late stages of infection. Membranes from
Chlamydia-infected HeLa cells were harvested at 0, 24,
36, and 48 hpi and purified, and the abundance of the
chlamydial proteins Ct005, IncC, and IncD was monitored
with specific antibodies. IncG and MOMP are an inclusion
membrane protein and an outer membrane protein,
respectively, that were determined not to be protease
sensitive. Na/K ATPase serves as host membrane loading
control.
See also Figure S1 and Table S2.
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system suggested that this protease can initiate a host cell death
pathway that mimics the necrotic cell death observed at the end
of the chlamydial life cycle (Paschen et al., 2008) and thus
contribute to acute inflammation and tissue scarring.Yet the signif-
icance of CPAF-mediated proteolysis during infection is unclear
due to the lack of specific CPAF inhibitors and the large number
and variability in host cell targets. Nonetheless, the abundance of
specific targets implies thatCPAF-mediatedproteolysis represents
a core strategy employed by Chlamydia to modify host-signaling
pathways and usurp the cellular machinery for its own benefit.
Here, we report that in addition to targeting host proteins, CPAF
cleaves bacterial effectors translocated during invasion and early
in inclusion biogenesis. We demonstrate that CPAF is essential
for bacterial replication, maintaining inclusion structural integrity
and evasion of caspase-1-dependent cell death in epithelial cells.
These results establish CPAF as a virulence factor required for
Chlamydia survival within infected cells and reveal unexpected
roles for this protease in regulating T3S effectors after their trans-
location into the host cell and in maintaining host cell viability.
RESULTS
A Subset of Chlamydia Effector Proteins Is Sensitive
to Proteolysis
Approximately 10% of the Chlamydia genome encodes proteins
that potentially access the cytoplasm of the infected host cell22 Cell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc.and act as effectors (Arnold et al., 2009) (A.H.
Saka and R.H.V., unpublished data). Because
effectors are secreted at distinct stages during
infection, we hypothesized that their activity in
the host cytoplasm is regulated as inappropriate
activity of effectors might negatively impact
bacterial growth. Since proteolysis is a commonmechanism of posttranslational control, we tested a panel of 309
recombinant Chlamydia-specific proteins, including known and
potential effector proteins, for sensitivity to proteolysis following
incubation with lysates from infected and uninfected HeLa cells
(Figure S1 available online). Thirty of the expressed chlamydial
proteins were sensitive to cytosols derived from infected cells
(Figure S1A). Protein processing ranged from the generation of
distinct cleavage fragments to complete degradation (Fig-
ure S1B). The protease-sensitive chlamydial proteins comprised
inclusion membrane proteins (n = 11), outer membrane proteins
(n = 3), proteases (n = 2), and open reading frames (ORFs) of
unknown function (n = 14) (Figure S1C and Table S2). Thirteen
of the 30 were also sensitive to proteolysis when treated with
lysates from uninfected cells, indicating that these proteins are
likely targets of host proteases (Figure 1A, Figures S1C–S1D,
and Table S2).
The Secreted Protease CPAF Cleaves a Subset
of Effector Proteins
Cleavage of nine chlamydial proteins was inhibited by pretreat-
ment of infected HeLa cytosols with lactacystin but not the unre-
lated proteosomal inhibitor MG132 and the peptide aldehyde
ALLN (Figure S1D and data not shown). Because this inhibitor
sensitivity profile is shared by CPAF (Pirbhai et al., 2006; Zhong
et al., 2000), we tested whether CPAF played a role in these
cleavage events by treating cytosols from infected HeLa cells
with anti-CPAF antisera. Anti-CPAF antisera, but not control
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CPAF Regulates Effectors and Inclusion Integrityantisera, blocked the degradation of recombinant bacterial
proteins (Figure S2A). In this manner, we determined that all
proteolysis-sensitive Chlamydia proteins were likely substrates
of CPAF (Figure 1A). We then tested whether CPAF was suffi-
cient for these cleavage events. Recombinant CPAF readily
cleaved Vimentin, a well-characterized CPAF substrate (Kumar
and Valdivia, 2008; Paschen et al., 2008) and GST-tagged chla-
mydial proteins Ct005, IncD (Ct115), IncE (Ct116), IncC (Ct233),
Ct288, CT694, CT695, Ct813, and TARP (Ct456) (Figure 1B). In
contrast, GST-tagged proteins that were identified as (1) not
sensitive to proteolysis, (2) sensitive to a non-CPAF chlamydial
protease, or (3) sensitive to a host protease were not cleaved
by recombinant CPAF (Figures S1D and S2B and data not
shown). Like endogenous CPAF, proteolysis by recombinant
CPAF was inhibited by lactacystin but not by MG132, ALLN,
or a range of serine protease inhibitors (Figure 1B and Fig-
ure S2C). The proteins identified as potential CPAF substrates
all contain putative T3S signals (Arnold et al., 2009) and fall
into two main categories: (1) experimentally validated effectors
that are prepacked into EBs (Clifton et al., 2004; Hower et al.,
2009) and (2) inclusion membrane proteins whose mRNAs are
expressed early (1–3 hr) after invasion (Belland et al., 2003)
(Figure 1C).
We next addressed whether the chlamydial CPAF substrates
were cleaved during infection. First, we expressed the EGFP-
taggedCPAF substrates Ct005 and IncD in HeLa cells and deter-
mined that these proteins were processed only upon Chlamydia
infection (Figure S2D). We generated antibodies against three of
these proteins (Ct005, IncC, and IncD) and confirmed by immu-
nofluorescence microscopy (IF) that they are expressed by 6 hr
after infection (Figure S2E). Because CPAF is not expressed until
later in infection (>18 hr), we predicted that if Ct005, IncC, and
IncD were CPAF substrates their abundance would decrease
with the onset of CPAF secretion. We assessed protein abun-
dance semiquantitatively by immunoblot analysis of membranes
isolated from Chlamydia-infected HeLa cells. The levels of major
outer membrane protein (MOMP) and the inclusion membrane
protein IncG, which are not CPAF substrates, increased
throughout infection, reflecting the increased bacterial loads in
these cells. In contrast, the levels of Ct005, IncC, and IncD
increased from 24–36 hr but dropped at 48 hr (Figure 1D). Over-
all, these experiments suggest an inverse correlation between
the onset of CPAF expression and the abundance of these three
secreted chlamydial proteins. Consistent with their potential as
bona fide CPAF targets, endogenous Ct005, IncC and IncD
from isolated membranes of Chlamydia-infected cells (24 hours
postinfection [hpi]) were efficiently cleaved by recombinant
CPAF in vitro (Figure S2F).
CPAF Cleaves Tarp during Chlamydia Entry
into Preinfected Cells
We identified the EB proteins Tarp and Ct694 as potential
substrates of CPAF-mediated degradation (Figures 1B and
1C). Tarp andCT694 are prepackaged into EBs and translocated
into the host cell during chlamydial invasion (Clifton et al., 2004;
Hower et al., 2009). Recombinant CPAF specifically degraded
Tarp and Ct694 from EB lysates, but not housekeeping proteins,
and its incubation with lysates did not result in the nonspecific
degradation of EB proteins (Figures S2G and S2H).COne scenario where Tarp and Ct694 would encounter CPAF
would be when an EB infects a cell that already contains
a mature inclusion. We predicted that under these conditions
Tarp translocated by EBs would be rapidly degraded. To test
this, we first compared the levels of Tarp at EB attachment
sites on uninfected versus preinfected HeLa cells. Tarp is phos-
phorylated at multiple tyrosine residues by host tyrosine
kinases (Jewett et al., 2008; Mehlitz et al., 2008), and IF staining
with anti-phosphotyrosine antibodies reveals a prominent cup
of immunoreactive material at EB attachment sites (Clifton
et al., 2004). We observed multiple phosphotyrosine-positive
foci immediately adjacent to EBs intimately attached to the
plasma membrane of HeLa cells. These foci, however, are
largely absent at EB attachment sites in HeLa cells that were
preinfected for 30 hr (Figures 2A and 2B), indicating that Tarp
translocation or phosphorylation is inhibited or that translo-
cated Tarp is degraded. To determine the stability of translo-
cated Tarp under these infection conditions, we infected
HeLa cells or inclusion-containing HeLa cells (30 hpi) with
35S-radiolabeled EBs and immunoprecipitated Tarp at 10 min
after infection. Radiolabeled Tarp, but not the outer membrane
protein MOMP, was degraded in HeLa cells harboring mature
inclusions but not in uninfected HeLa cells (Figure 2C). Overall,
these experiments indicate that EB-associated effectors, like
the early inclusion membrane proteins described above, are
subject to degradation in a manner that correlates with the
presence of CPAF.
A Cell-Permeable CPAF-Specific Inhibitory Peptide
Prevents CPAF Cleavage of Host and Chlamydia
Substrates
Because the lack of a system for genetic manipulation of
Chlamydiae precludes the generation of CPAF-deficient mutants
or the mutation of CPAF cleavage sites in effectors, it is difficult
to directly test the functional consequence of these proteolytic
events. However, recent structural information on CPAF (Huang
et al., 2008) provided the basis for the design of a CPAF-specific
inhibitory peptide (SLFYSPMVPHFWAELRNHYATSGLK) that
occludes the active site of the mature enzyme. This CPAF
peptide258–283 is removed during autocatalytic activation of the
zymogen. As a control, we synthesized a scrambled version of
the peptide. To facilitate delivery and uptake into mammalian
cells we included a C-terminal nine-Arg tail on both peptides
(Stewart et al., 2008). We tested the efficiency of the poly-Arg-
tagged CPAF-inhibitory peptide in vitro using an HPLC-based
enzyme assay that measures the cleavage of an Abz-tagged
Vimentin derived peptide (Abz-VRLRSSVPGV-NH2). The ‘‘anti-
CPAF peptide’’ blocked CPAF-mediated proteolysis with
100-fold higher efficiency than lactacystin, the only known
inhibitor of CPAF (Figure 2D). The anti-CPAF peptide, but not
the scrambled control peptide, also inhibited cleavage of
GST-tagged chlamydial substrates and GST-Vimentin in vitro
(Figure 2E and data not shown). Importantly, the anti-CPAF
peptide inhibited cleavage of Vimentin and Puma within infected
epithelial cells (Figure 2F), indicating that mammalian cells effi-
ciently internalize the peptide and that CPAF activity can be in-
hibited within live, infected cells. Moreover, the CPAF-inhibitory
peptide did not induce any obvious toxicity or alter proteasome
function in uninfected cells (data not shown).ell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc. 23
Figure 2. A Cell-Permeable CPAF-Specific Inhibitory Peptide Blocks Cleavage of Chlamydia Effectors during Infection
(A–C) Tarp translocated by EBs is a target of CPAF-mediated degradation. Uninfected HeLa cells and HeLa cells preinfected with L2 for 30 hr were treated
with a cell-permeable polyarginine tagged CPAF-inhibitory (‘‘anti-CPAF’’) peptide and infected with EBs for 10 min. Tarp translocation was indirectly visu-
alized with an anti-phosphotyrosine antibody (A) and quantified in 50 separate cells (B). Error bars represent ± standard error (B). The stability of newly
translocated Tarp was assessed by infecting cells as in (A) but with S35-labeled EBs, followed by sequential immunoprecipitation of Tarp and MOMP and
PhosphoImager analysis of precipitated material (C). Note the CPAF-dependent Tarp degradation in preinfected HeLa cells. Error bars represent ± standard
deviation (SD) (C).
(D) Inhibition of CPAF activity by inhibitory peptide. IC50 values were assessed by monitoring the cleavage of a synthetic fluorophore-tagged, Vimentin-derived
substrate by HPLC. Assays were performed in the presence of increasing amount of inhibitors. The IC50 values of the anti-CPAF peptide and lactacystin were
0.05 mM ± 0.007 SD and 10 mM ± 2.3 SD, respectively.
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Tarp degradation upon secondary infections. Indeed, anti-
CPAF peptide restored the accumulation of Tyr-phosphorylated
proteins at EB attachment sites on preinfected cells (Figure 2B)
and partially blocked the degradation of Tarp in pulse-chase
experiments (Figure 2C), suggesting that Tarp may be a target
for other host or bacterial proteases. Overall, these observations
strongly suggest that early Chlamydia effectors are in vivo
targets of CPAF and that a CPAF-specific inhibitory peptide
can efficiently inhibit CPAF activity both in vitro and in vivo.
We postulated that CPAF-mediated degradation of effectors
secreted by EBs during invasion may protect preinfected cells
against superinfection. To test whether infected cells are refrac-
tory to reinfection, we quantified the number of EBs internalized
by uninfected cells and preinfected cells. We observed a signifi-
cant decrease in the number of newly internalized EBs in cells
that contains a mature inclusion compared to uninfected cells
(Figure 2G). This resistance to reinfection is partially mediated
by CPAF, as treatment of preinfected cells with anti-CPAF
peptides increased EB entry (Figure 2H).
CPAF Activity Is Required for Chlamydia Replication
and Integrity of the Inclusion
While CPAF has well-established functions in the downregula-
tion of immune responses, proapoptotic factors, and the
processing of cytoskeletal proteins (Zhong, 2009), the role that
these proteolytic events play in bacterial replication and intracel-
lular survival is unknown. We treated Chlamydia-infected cells
with anti-CPAF peptide and determined that peptide treatment
significantly lowered yields of EBs and stunted inclusion growth
(Figure 3A and Figures S3A and S3B). To assess the specificity
of this peptide, we tested the effect of anti-CPAF peptide on
HeLa cells infected with C. muridarum and C. caviae, two
chlamydial species that display varying degrees of CPAF
sequence conservation (Figure S3C). Consistent with the
high degree of conservation between C. trachomatis and
C. muridarum CPAFs, the anti-CPAF peptide prevented
cleavage of substrates by C. muridarum CPAF (Figure S3D)
and blocked C. muridarum replication (Figure S3E). In contrast,
the divergent C. caviae CPAF was not sensitive to the anti-
CPAF peptide in vitro or in vivo (Figures S3D and S3F).
Next, we assessed the mechanism underlying the inhibition of
Chlamydia replication by performing a microscopic analysis of
infected cells treated with anti-CPAF peptide. Prolonged inhibi-
tion of CPAF (>8 hr) with the anti-CPAF peptide, but not the
scrambled control peptide, led to the collapse of the inclusion
with the inclusion membrane markers localizing to perinuclear
aggregates and dispersed bacteria (Figure 3B and Figure S4I).
Analysis of these cells by transmission electron microscopy(E and F) Anti CPAF peptide, but not a scrambled control peptide, broadly inhibit
chlamydial substrates was performed as in Figure 1B but in the presence of anti-C
(L2), infected HeLa cells were treatedwith peptide at 12 hpi, and harvested at 30 hp
CPAF peptide.
(G and H) CPAF restricts EB entry into preinfected cells. Cells were infected a
fluorescently labeled EBs (green) and infected cells were not permeabilized. Ext
immunoreactivity to anti-L2 antibodies (red). Extracellular bacteria appear yellow (
of internalized EBs was quantified per cell (H). Representative of two experimen
See also Figure S2.
Cconfirmed the loss of inclusion integrity and disruption of the
inclusion membrane with intact Chlamydia freely residing in the
cytoplasm (Figure 3C). Accordingly, we observed a loss of
Vimentin re-organization around the inclusion (Figure 3D), which
has been previously linked to inclusion stability (Kumar and Val-
divia, 2008). Consistent with the presence of intact bacteria in the
cytoplasm, we also observed enhanced secretion of IL-8 (Fig-
ure 3E). Hence, we conclude that CPAF functions to maintain
inclusion integrity during infection.
Inhibition of CPAF Induces Caspase-1-Dependent
Cell Death
In addition to limiting inclusion growth, treatment with anti-CPAF
peptide led to a marked increase in the number of infected
epithelial cells with condensed nuclei (Figure 4A and Figures
S4A and S4B). This effect is specific to CPAF, as the anti-
CPAF peptide did not lead to host cell death inC. caviae-infected
cells (Figures S4E and S4F). Cell death occurred after 20 hpi (Fig-
ure 4A), which coincides with the translocation of CPAF into the
host cytoplasm and was observed in several nonmyeloid cell
lines (Figures S4C and S4D). Besides resulting in a ruptured
inclusion and cell death, inhibiting CPAF also led to the formation
of multiple inclusions and small inclusions (Figure S4H). Given
that Chlamydia-infected cells are highly resistant to intrinsic
and extrinsic apoptotic stimuli (Greene et al., 2004) and that
proapoptotic BH3-only proteins are CPAF targets (Paschen
et al., 2008; Pirbhai et al., 2006), we hypothesized that CPAF
inhibition led to the onset of apoptosis in infected cells. To test
this, we labeled infected cells with propidium iodide and Annexin
V to monitor cell viability and the loss of plasma membrane
symmetry—a hallmark of apoptosis (Vermes et al., 1995).
Chlamydia-infected cells treated with anti-CPAF peptide did
not stain with Annexin V, indicating that the cell death is unlikely
the result of classical apoptosis (Figure 4B). Consistent with this
observation, we did not detect caspase-3 cleavage, another
feature of apoptotic cell death (Figure 4C) (Galluzzi et al., 2009).
Unexpectedly, the pancaspase inhibitor Ac-ZVAD-FMK effi-
ciently blocked the death of infected cells treated with anti-CPAF
peptide (Figure 4D). In myeloid cells, activation of caspase-1 by
infectious agents can lead to pyroptosis, a cell death pathway
accompanied by pore formation and the release of proinflamma-
tory modifiers (Brennan and Cookson, 2000; Cervantes et al.,
2008; Jesenberger et al., 2000). However, it is unclear whether
this process also occurs in epithelial cells. We determined that
the caspase-1 inhibitor Ac-YVAD-cmk efficiently blocked the
death of infected epithelial cells treated with anti-CPAF peptide
(Figure 5A). In addition, we observed that caspase-1 activity,
as assessed with a fluorescently labeled caspase-1 substrate
(Darzynkiewicz et al., 2011), was significantly increased durings degradation of CPAF substrates in vitro and in vivo. CPAF cleavage of GST-
PAF or scrambled control peptide (E). For in vivo inhibition effects onChlamydia
i (F). Vimentin and Puma cleavage is inhibited in infected cells treatedwith anti-
s in (A), except that the secondary infections (30 min) were performed with
racellular EBs were distinguished from intracellular EBs (green) based on their
G). Also note clustering of internalized bacteria at a perinuclear site. The number
ts performed in duplicate (n = 40 cells). Error bars represent ± standard error.
ell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc. 25
Figure 3. CPAF Is Required for Chlamydia Replication and Inclusion Maintenance
(A) Anti-CPAF peptide blocks the generation of Chlamydia infectious particles. L2-infected HeLa cells were treated at 12 hpi with increasing concentration of
peptide. EBs were harvested at 30 hpi, and inclusion forming units (IFUs) were quantified. Error bars represent ± standard error.
(B–D) CPAF activity is required tomaintain inclusion integrity. DNAwas stained with Hoechst (blue). Inclusion integrity was assessed by immunolocalization of the
inclusion membrane marker IncA (red) and Chlamydia (green) (B) and by transmission electron microscopy (C). Note collapse of IncA-positive membranes and
loss of inclusion integrity with bacteria in the cytoplasm (arrows) of infected cells lacking CPAF activity (right panels). (D) Vimentin-positive inclusions were
identified by IF of infected cells fixed 24 hpi subsequent to treatment with control and inhibitory peptide at 12 hpi. Error bars represent ± standard error.
(E) Inhibition of CPAF activity leads to activation of inflammatory cytokines. Levels of IL-8 in supernatants from Chlamydia-infected cells treated with inhibitory
peptide as in (B)–(D) were determined by ELISA at 24 hpi. Error bars represent ± standard error.
See also Figure S3.
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confirmed the role played by caspase-1 and its upstream acti-
vator, the inflammasome adaptor protein ASC (Martinon et al.,
2002), in mediating cell death by infecting transformed mouse26 Cell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc.lung fibroblasts (MLFs) derived from caspase-1 (ICE/) and
ASC (Pycard/) knockout mice with C. trachomatis and
C. muridarum. These MLFs, unlike their wild-type counterparts,
were resistant to host cell death in response to treatment with
Figure 4. Inhibition of CPAF Activity Induces Nonapoptotic Death
of Host Cells
(A) Inhibiting CPAF activity induces host cell death. Inhibitory peptide was
added to infected HeLa cells 12 hpi, and the percentage of infected cells with
condensed nuclei was quantified at the indicated times. Error bars represent ±
standard error.
(B and C) Inhibition of CPAF activity does not induce apoptosis. Infected cells
were treated with inhibitory peptide and the percentage of AnnexinV-FITC
positive cells among propidium iodide (PI) negative cells was determined by
flow cytometry (B). In parallel samples, cleavage of caspase-3, a hallmark of
apoptosome activation, was monitored by immunoblot analysis. Actin and
MOMP are host and bacterial loading controls, respectively. Treatment with
staurosporine (2 mM) and the pancaspase inhibitor Ac-ZVAD-fmkwere used as
controls for the induction of apoptosis and caspase activity, respectively. Error
bars represent ± standard error.
(D) The pancaspase inhibitor Ac-ZVAD-FMK blocks death of Chlamydia-
infected epithelial cells. Infected HeLa cells were treated as in (A) in the
presence or absence of Ac-ZVAD-fmk. Cell toxicity was determined by flow
cytometry of PI-stained cells. PI staining was not seen in cells pretreated
with Ac-ZVAD-fmk or the scrambled control peptide. Error bars represent ±
standard error.
See also Figure S3.
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Canti-CPAF peptide, indicating that inflammasome-dependent
activation of caspase-1 is required for cell death (Figure 5C
and Figure S4G). Interestingly, pharmacological or genetic inhi-
bition of caspase-1 did not rescue bacterial replication (Figure 5D
and Figure S3E). Overall, these findings indicate that CPAF plays
at least two distinct roles in promoting chlamydial replication:
mediating inclusion stability and suppressing caspase-1 depen-
dent cell death.DISCUSSION
Chlamydia effector proteins, in a life cycle- and stage-dependent
manner, control bacterial entry, establishment of a replicative
vacuole, modulation of innate immune responses, and, ulti-
mately, exit from the host cell (Valdivia, 2008). The deployment
of such a vast arsenal of bacterial proteins into the mammalian
cytoplasm presents two challenges for Chlamydia: (1) how to
limit the detection of these microbe-derived proteins by innate
immune surveillance pathways and (2) how to control the func-
tion of these proteins after they leave the confines of the bacterial
cell. Here, we present evidence that CPAF, a chlamydial
protease that modulates multiple host functions required for
innate and adaptive immunity (Zhong, 2009), also cleaves
a subset of effector proteins that are translocated early during
infection. The concept of a ‘‘meta’’ effector, one that regulates
the function of others, was proposed for the Legionella E3 ubiq-
uitin ligase LubX, which ubiquitinates the effector SidH and
targets it for degradation (Kubori et al., 2010). Our data suggests
that CPAF serves a similar function by directly cleaving a subset
of secreted effectors and inclusion membrane proteins.
Because CPAF is translocated into the cytoplasm starting at
16 hr after infection (Shaw et al., 2002), the inclusion membrane
proteins we identified as CPAF substrates are unlikely to be
cleaved until the middle stage of the infectious cycle. This is
consistent with the observation that the steady-state levels of
Ct005, IncC, and IncD do not decrease until later in infection
(Figure 1D). CPAF cleavage of Incs during midcycle may
be less efficient due to Inc modification or formation of Incell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc. 27
Figure 5. Death of Chlamydia-Infected Cells Treated with CPAF-Inhibitory Peptide Is Dependent on Caspase-1
(A) Caspase-1 inhibitors block Chlamydia-mediated cell death. Infected HeLa cells were treated with inhibitory peptide at 12 hpi, fixed at 24 hpi, and the
percentage of cells with condensed nuclei was quantified. Ac-YVAD-cmk was added at 2 hpi. Error bars represent ± standard error.
(B) Caspase-1 activation is enhanced during infection when CPAF is inhibited. Infected cells were labeled with a cell-permeable fluorescent substrate of caspase-
1 and treated with anti-CPAF peptide, and caspase-1 activity at 28 hr after infection was monitored by flow cytometry.
(C) Caspase-1 and ASC are required for Chlamydia-mediated host cell death. Chlamydia-infected lung fibroblasts derived from caspase-1 (ICE/) and ASC
adaptor (ASC/) knockout mice were resistant to cell death induced by anti-CPAF peptide. Error bars represent ± standard error.
(D) CPAF is required for chlamydial replication independently of its role in suppressing caspase-1-mediated cell death. Chlamydia replication and generation of
IFUs in MLFs was assessed as in Figure 3. Note dose-dependent loss in IFU yields in all MLF lines. Error bars represent ± standard error.
See also Figure S4.
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substrate-specific features (e.g., secondary or tertiary structure)
may influence the efficiency of CPAF-mediated processing.
Among the 42 putative Inc proteins (Li et al., 2008) tested, only
four were identified as CPAF substrates (Figure 1), and three
of these are predicted to be expressed within the first 3 hr of
infection (Belland et al., 2003). Notably, not all Inc proteins
were targets of degradation, suggesting that CPAF strategically
removes a subset of Inc proteins rather than achieving a whole-
sale remodeling of the inclusion membrane. Inc proteins are
predicted to perform multiple functions, including protection
from apoptosis (Verbeke et al., 2006), sequestration of signaling
proteins (Mital et al., 2010), and rerouting of membrane transport
(Rzomp et al., 2006). We postulate that factors required early in
the biogenesis of the inclusion may not be necessary for—or
may even be detrimental to—optimal inclusion expansion later
in the infectious cycle. As such, cleavage of these early Inc
proteins may be essential to the chlamydial life cycle. It is also
possible that CPAF cleavage of Inc proteins may limit their
detection by microbial pattern recognition receptors or their
processing and display by MHC class I molecules (Roan and
Starnbach, 2008). Given CPAF degradation of transcription
factors required for MHC-I and MHC-II expression (Zhong
et al., 2001), cleavage of Inc proteins could further reduce the
possibility of these proteins being presented as antigens.
Two chlamydial CPAF targets (Tarp and Ct694) are translo-
cated during EB attachment. One condition under which EB
effectors would encounter CPAF in the host cytoplasm is if an
EB where to infect a cell that already had an established inclu-
sion. In such a scenario, CPAF would play a role in preventing
the establishment of secondary inclusions thatmay impair devel-
opment of the primary inclusion. Consistent with this, Tarp trans-
located by EBs into cells with established inclusions is rapidly
degraded (Figure 2). This degradation is partially blocked upon
delivery of a peptide-based CPAF inhibitor, indicating that Tarp28 Cell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc.is a true target of CPAF-mediated degradation. Accordingly,
EBs are blocked from entering a cell that contains amature inclu-
sion, but this is reversed when CPAF activity is inhibited. Collec-
tively, CPAF may therefore mediate resistance to superinfection
by degrading secreted effectors involved in invasion and early
inclusion biogenesis.
CPAF-specific inhibitors revealed that this protease plays an
essential role in chlamydial development and replication (Figure 3
and Figures S4 and S5). Inclusion growth was stunted concom-
itantly with a drop in the generation of infectious progeny and
marked increase in toxicity to the infected cell (Figures 3 and
4). The most striking effect of anti-CPAF peptide was the loss
of inclusion integrity in treated cells. Whether this is the conse-
quence of a lack of Inc protein turnover or processing of interme-
diate filaments at the inclusion membrane is unclear. Regardless
of the sequence of events leading to inclusion membrane
dismantling, it is apparent that this protease plays an essential
role in maintaining the integrity of the pathogenic vacuole.
CPAF is predicted to both prevent (Pirbhai et al., 2006) and
promote (Paschen et al., 2008) cell death depending on the stage
of infection. The prosurvival mechanismof CPAFmay include the
degradation of proapoptotic proteins, and indeed, we found that
anti-CPAF peptide blocked the cleavage of Puma (Figure 2C).
However, Chlamydia-infected cells treated with anti-CPAF
peptide initiated a cell death program that did not resemble
classical apoptosis. Instead, we found that death of infected
epithelial cells upon inhibition of CPAF activity was dependent
on caspase-1 and that anti-CPAF inhibitors led to an early
activation of caspase-1 (Figures 3 and 5). In myeloid cells, cas-
pase-1 dependent cell death—also termed pyroptosis—results
in rapid plasma membrane rupture and release of proinflamma-
tory cytokines such as IL-1b and IL-18 (Bergsbaken et al., 2009).
Pore formation in the plasma membrane disrupts ionic gra-
dients, which increases the osmotic pressure leading to swelling
and lysis. Normally, caspase-1-mediated cell death aids in the
Figure 6. CPAF Mediates Resistance to Reinfection, Inclusion Integrity, and Protection from Caspase-1-Mediated Cell Death
CPAF reorganizes intermediate filaments at the inclusion periphery to promote inclusion stability (Kumar and Valdivia, 2008) and mediates protection
from reinfection by targeting effectors translocated during invasion and early inclusion biogenesis. Inhibition of CPAF activity leads to a loss of protection from
re-infection. In addition, CPAF activity is required to maintain inclusion membrane integrity, dampen the secretion of proinflammatory cytokines, and prevent
inflammasome-dependent activation of caspase-1-dependent cell death.
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Brennan and Cookson, 2000; Sansonetti et al., 2000). Recently,
it has been reported that Chlamydia infection activates caspase-
1 in epithelial cells late during infection and is required for optimal
chlamydial growth (Abdul-Sater et al., 2009; Lu et al., 2000).
Potentially, the dependence of chlamydial growth on caspase-
1 is a consequence of enhanced lipid biosynthesis that occurs
upon activation of low levels of caspase-1 (Gurcel et al., 2006).
However, upon inhibition of CPAF, caspase-1 activation occurs
much earlier and with greater magnitude, most likely as a result
of an overwhelming response to bacterial products in the cyto-
plasm. We predict that this premature activation of caspase-1
triggers an irreversible cell death program in Chlamydia-infected
nonmyeloid cells, as has been recently proposed in Salmonella
that resides in the cytoplasm of infected colonic epithelial cells
(Knodler et al., 2010). It is also possible that CPAF plays
a more direct role in suppressing inflammasome formation as
has been demonstrated for the Yersinia effectors YopE and
YopT (Schotte et al., 2004) and the poxvirus pyrin-domain
protein M13L (Johnston et al., 2005).
Overall, these studies establish that CPAF is an essentialChla-
mydia virulence factor with an important role in maintaining the
integrity of the inclusion and preventing the premature death of
its host cell in a single cell, autonomous tissue culture model of
infection (Figure 6). Furthermore, CPAF plays a previously unap-
preciated role in the turnover of other effectors to aid in the re-
modeling of the inclusion and to limit secondary infections.
Consistent with its obligate intracellular lifestyle and its small
genome, it is not surprising that Chlamydia has become adeptCat multitasking by expressing regulatory effectors with multiple
functions, like CPAF. Thus, CPAF emerges as a central virulence
protein and an attractive target for the design of specific
protease inhibitors for therapeutic intervention.EXPERIMENTAL PROCEDURES
Expression Constructs and Proteolysis Screen
C. trachomatis ORFs cloned into the yeast expression vector pSDY8
(C-terminal GFP tag) (Sisko et al., 2006) or the E. coli expression vector
pGEX-4T-1 vector (GEHealthcare) are listed in Table S1. Hexahistidine-tagged
CPAF (pET30b) was purified as previously described (Huang et al., 2008). For
in vitro cleavage assays, Chlamydia proteins fused to EGFP or GST were ex-
pressed in yeast and E. coli, respectively. Yeast lysates or purifiedGST-tagged
were incubated with cytosols from uninfected or LGV-L2-infected (40 hr) HeLa
cells for 30 min at 37C. Processed chlamydial proteins were detected by
immunoblot analysis with anti-GFP antibodies or Coomassie blue staining.
Cell Culture and Chlamydia Infections
MLFs from Pycard/, ICE/, and WT mice were isolated as previously
described (van Deventer et al., 2008). Ex vivo lungs were minced, incubated
with 1 mg/ml collagenase A, and 20 mg/ml DNase I in RPMI supplemented
with 2% fetal calf serum (FBS) for 45 min at 37C. Digested lungs were filtered
and washed, and red blood cells were lysed in NH4CaK buffer. Cultured MLFs
were immortalized by lentiviral-mediated transduction of T antigen and human
telomerase as previously described (O’Hayer and Counter, 2006). HeLa cells
(ATCC)andMLFsweremaintained inDMEMsupplementedwith10%FBS(Cell-
Gro Mediatech). C. trachomatis LGV-L2 434/Bu was propagated in HeLa cells
as previously described (Caldwell et al., 1981). EBs were added to HeLa cells
at the indicated multiplicities of infection (MOIs), and infections were synchro-
nized by centrifugation at 300 3 g for 30 min at 4C. C. muridarum Nigg and
C. caviae stocks were kind gifts from Roger Rank (University of Arkansas).ell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc. 29
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Rabbits were immunized with recombinant GST fusions to Ct005, IncC, IncD,
Tarp (Ted Hackstadt, Rocky Mountain Laboratories/National Institutes of
Health), and hexahistidine-tagged CPAF (J. Chai, Institute of Biological
Sciences, Beijing) produced in E. coli BL21-DE3 (Stratagene) and purified by
affinity chromatography. IgG antibodies were purified with protein A-coated
Sepharose beads (GEHealthcare). Membrane-associated chlamydial proteins
were harvested from infected HeLa by ultracentrifugation of whole-cell lysates
on an Optiprep (Sigma) discontinuous density gradient (25%, 20%, 17.5%,
15%, 12.5%, 10%) and assessing the fractionation of IncA- and IncG-positive
membranes by immunoblot analysis. For assessment of CPAF cleavage of
membrane proteins and EB proteins, purified membranes and soluble EB
protein lysate were incubated with 6xHis-CPAF at 37C for 20 min, and the re-
sulting product was analyzed by immunoblots with specific antibodies.
Generation of Inhibitory Peptide and CPAF Cleavage Assays
The anti-CPAF peptide (SLFYSPMVPHFWAELRNHYATSGLKRRRRRRRRR)
and scrambled control (NFALSHFRLPLSTYKEMPYVSHWAGRRRRRRRRR)
peptide were synthesized by solid-phase peptide synthesis by the FMOC
t-Boc method. Peptides were purified to homogeneity by reverse-phase
HPLC and confirmed bymass spectrometry. Scaled up production of peptides
were performed by Eton Biosciences (Durham, NC) and purified by HPLC. IC50
values were determined by assessment of cleavage inhibition of an Abz-
tagged Vimentin peptide VRLRSSVPGV-NH2. His-CPAF was preincubated
with 10 mM lactacystin (EMD), solvent control (DMSO), ACP, or CP at 37C
for 30 min. Cleavage products were assessed by HPL analysis. For assess-
ment of CPAF-dependent cleavage during infection, 1.2 3 106 HeLa cells
were grown in 6-well plates and infected with LGV-L2 at an MOI of 1, treated
with anti-CPAF or control peptide at 12 hpi and harvested at 30 hpi.
Immunofluorescence Microscopy
A detailed list of antibodies used in this study is available in Table S3. For
routine indirect immunofluorescence, 0.2 3 106 HeLa cells were grown on
glass coverslips and infected at the indicated MOI. Cells were fixed with
cold 3% formaldehyde in phosphate-buffered saline (PBS), permeabilized
with 0.1% Triton X-100, blocked in 2% bovine serum albumin (BSA), and incu-
bated with the specified primary antibodies in 2% BSA in PBS and fluoro-
phore-conjugated anti-rabbit or anti-mouse goat IgG (Molecular Probes).
Host and bacterial DNA were stained with 1 mM Hoechst in PBS (Invitrogen).
Infected cells were imaged with a Zeiss Axioscope epifluorescence micro-
scope and Axiovision v3.0 software or a Leica TCS SL confocal microscope
and processed with Leica software. For transmission electron microscopy
(TEM), HeLa cells grown on thermanox (Electron Microscopy Services) cover-
slips were infected with LGV-L2 and treated with anti-CPAF peptide as
described above, fixed with 0.05% malachite green/2.5% gluteraldehyde,
postfixed with 0.8% osmium tetroxide and 1% tannic acid and 1% uranyl
acetate. After dehydration with ethanol of samples, sections were poststained
and imaged with a Tecnai G12 Twin electron microscope (FEI).
Radiolabeling and Secondary Infections
HeLa cells were infected withC. trachomatis for 18 hr and labeled with 300 mCi
S35 cysteine/methionine (Perkin Elmer) in the presence of 40 mg/ml cyclohex-
amide (Sigma) for an additional 22 hr. EB seed was harvested following gentle
sonication and stored at80C in SPG buffer (0.25 M sucrose, 10 mM sodium
phosphate, 5 mM L-glutamic acid). Uninfected or HeLa cells that had been
preinfected for 30 hr were infected with unlabeled or S35-labeled LGV-L2
seed at an MOI of 50. Cells were washed extensively with trypsin, and har-
vested at 10 min after the secondary infection in lysis buffer (20 mM Tris,
150 mMNaCl, 1% Tx100, 2 mM PMSF, 2 mMMG132, 10 mM ALLN, protease
inhibitor cocktail [Roche]). Tarp and MOMP were immunoprecipitated with
anti-TARP and anti-MOMP polyclonal antisera and protein A-coated Sephar-
ose beads (GE Healthcare), detected in a Typhoon9410 Variable Image Phos-
phorImager (Amersham Biosciences), and quantified with ImageQuant 5.1TL
(GE Healthcare). To test the effect of inhibitory peptide, cells were treated
with 12 mMpeptides for the duration of the secondary infections. To distinguish
intracellular from extracellular EBs, cells were infected with CellTracker (Invi-
trogen)-labeled EBs for 30 min, fixed without premeabilization and extracel-
lular EBs were immunostained with an anti-LGV-L2 antisera.30 Cell Host & Microbe 10, 21–32, July 21, 2011 ª2011 Elsevier Inc.Cytokine, Apoptosis, and Caspase-1 Activation Assays
HeLa cells were infected with C. trachomatis LGV-L2 at an MOI of 1. At 3 hpi,
cells were treated with 40 mM Z-VAD-FMK (Promega) or 400 mM Ac-YVAD-
cmk (Enzo Life Sciences). At 12 hpi, cells were treated with 12.5 mM of anti-
CPAF peptide or control peptide. IL-8 secretion into themedia was determined
with a Human IL-8 ELISA kit (BioLegend) as recommended by the manufac-
turer. Apoptotic cells were identified with an AnnexinV-FLOUS Staining Kit
(Roche) and activation of caspase-1 was determined by labeling active cas-
pase-1 with a Carboxyfluorescein FLICA Detection Kit (Immunochemistry)
and analyzed in a FACScanner (BD).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and three tables and can be
found with this article online at doi:10.1016/j.chom.2011.06.008.
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